William Huynh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5508599/publications.pdf

Version: 2024-02-01

68 1,458 20 35 g-index

77 77 77 1932

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Prognostic indicators of subacute combined degeneration from <scp>B12</scp> deficiency: A systematic review. PM and R, 2022, 14, 504-514.	1.6	1
2	The changing landscape of neuroimaging in frontotemporal lobar degeneration: from group-level observations to single-subject data interpretation. Expert Review of Neurotherapeutics, 2022, 22, 179-207.	2.8	8
3	Multiple cranial nerve enlargement in Charcot-Marie-Tooth disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 216-217.	1.9	1
4	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
5	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open, 2021, 11, e041479.	1.9	33
6	Mills Syndrome. Neurology, 2021, 96, 677-678.	1.1	2
7	Apathy is associated with parietal cortical-subcortical dysfunction in ALS. Cortex, 2021, 145, 341-349.	2.4	12
8	Teaching Video Neurolmage: Clenched Fists as an Unusual Presentation of Focal Neuromyotonia. Neurology, 2021, 97, e429-e430.	1.1	0
9	Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. CNS Drugs, 2021, 35, 483-505.	5.9	13
10	Behavioural changes predict poorer survival in amyotrophic lateral sclerosis. Brain and Cognition, 2021, 150, 105710.	1.8	17
11	Illness Cognitions in ALS: New Insights Into Clinical Management of Behavioural Symptoms. Frontiers in Neurology, 2021, 12, 740693.	2.4	2
12	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage. Frontiers in Neurology, 2021, 12, 743688.	2.4	6
13	Syphilitic gumma presenting as myelopathy. Journal of Clinical Neuroscience, 2020, 74, 256-257.	1.5	2
14	Respiratory function and cognitive profile in amyotrophic lateral sclerosis. European Journal of Neurology, 2020, 27, 685-691.	3.3	12
15	Clinicoradiological dissociation in sarcoid myelopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1227-1228.	1.9	O
16	The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 281-293.	2.8	48
17	A novel phenotype of hereditary spastic paraplegia type 7 associated with a compound heterozygous mutation in paraplegin. Muscle and Nerve, 2020, 62, E44-E45.	2.2	1
18	Electrophysiological and phenotypic profiles of taxane-induced neuropathy. Clinical Neurophysiology, 2020, 131, 1979-1985.	1.5	14

#	Article	IF	CITATIONS
19	Extraneural ganglionic cysts causing tarsal tunnel syndrome. Clinical Neurophysiology, 2020, 131, 1241-1242.	1.5	4
20	Neurorehabilitation approaches for disorders of the peripheral nervous system., 2020,, 253-268.		0
21	Transcranial magnetic stimulation in the cortical exploration of dementia., 2020,, 327-343.		1
22	Interrogating cortical function with transcranial magnetic stimulation: insights from neurodegenerative disease and stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 47-57.	1.9	29
23	042â€Respiratory function and cognitive profile in motor neuron disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A14.2-A14.	1.9	0
24	Implications of structural and functional brain changes in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2018, 18, 407-419.	2.8	12
25	Excitability of sensory axons in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 1472-1478.	1.5	9
26	Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 974-980.	1.5	15
27	Recreational nitrous oxide-associated neurotoxicity. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 897-898.	1.9	21
28	Motor neurone disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 159, 345-357.	1.8	10
29	The provision of written information and its effect on levels of pain and anxiety during electrodiagnostic studies: A randomised controlled trial. PLoS ONE, 2018, 13, e0196917.	2.5	6
30	Fasciculation intensity and disease progression in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 2149-2154.	1.5	20
31	Comparison of crossâ€sectional areas and distalâ€proximal nerve ratios in amyotrophic lateral sclerosis. Muscle and Nerve, 2018, 58, 777-783.	2.2	27
32	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. Clinical Neurophysiology, 2018, 129, 2162-2169.	1.5	15
33	Functional Biomarkers for Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1141.	2.4	23
34	Utility of maximum perfusion intensity as an ultrasonographic marker of intraneural blood flow. Muscle and Nerve, 2017, 55, 77-83.	2.2	24
35	Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 474-483.	1.9	93
36	Quantitative muscle ultrasound as a biomarker in Charcot-Marie-Tooth neuropathy. Clinical Neurophysiology, 2017, 128, 227-232.	1.5	25

#	Article	IF	Citations
37	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	10.2	62
38	Detection of fasciculations in amyotrophic lateral sclerosis: The optimal ultrasound scan time. Muscle and Nerve, 2017, 56, 1068-1071.	2.2	30
39	Cortical function and corticomotoneuronal adaptation in monomelic amyotrophy. Clinical Neurophysiology, 2017, 128, 1488-1495.	1.5	9
40	The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2017, 128, 1075-1082.	1.5	34
41	The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. Diabetes, 2017, 66, 1661-1670.	0.6	17
42	Extraneural ganglion cyst as a rare cause for footdrop. Muscle and Nerve, 2017, 56, E173-E174.	2.2	0
43	Immune dysregulation in patients with carpal tunnel syndrome. Scientific Reports, 2017, 7, 8218.	3.3	16
44	Facial weakness and eyelid ptosis: Expanding the clinical heterogeneity of Bethlem myopathy from a novel gene mutation. Muscle and Nerve, 2017, 55, E2-E3.	2.2	1
45	Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. Muscle and Nerve, 2017, 55, 424-427.	2.2	10
46	Is Google good enough for medicine?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 915-915.	1.9	0
47	Effect of fampridine on axonal excitability in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 2636-2642.	1.5	10
48	Motor cortical function determines prognosis in sporadic ALS. Neurology, 2016, 87, 513-520.	1.1	76
49	Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2016, 127, 2643-2660.	1.5	87
50	Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. Clinical Neurophysiology, 2016, 127, 2355-2361.	1.5	33
51	Large intracranial meningioma masquerading as Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1251-1251.	1.9	1
52	Exploring the Evolution of Cortical Excitability Following Acute Stroke. Neurorehabilitation and Neural Repair, 2016, 30, 244-257.	2.9	40
53	Motor neuron disease: current management and future prospects. Internal Medicine Journal, 2015, 45, 1005-1013.	0.8	18
54	Peripheral nerve axonal excitability studies: expanding the neurophysiologist's armamentarium. Cerebellum and Ataxias, 2015, 2, 4.	1.9	9

#	Article	IF	CITATIONS
55	A unique account of ALS in China: exploring ethnic heterogeneity. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1051-1052.	1.9	6
56	Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis. Current Medicinal Chemistry, 2015, 22, 4366-4378.	2.4	11
57	Reply: Botulinum toxin injection for postâ€stroke spasticity. Muscle and Nerve, 2014, 49, 932-933.	2.2	O
58	Transynaptic Changes Evident in Peripheral Axonal Function After Acute Cerebellar Infarct. Cerebellum, 2014, 13, 669-676.	2.5	9
59	Motor Cortex Excitability in Acute Cerebellar Infarct. Cerebellum, 2013, 12, 826-834.	2.5	16
60	Longitudinal Plasticity Across the Neural Axis in Acute Stroke. Neurorehabilitation and Neural Repair, 2013, 27, 219-229.	2.9	35
61	Botulinum toxin modulates cortical maladaptation in postâ€stroke spasticity. Muscle and Nerve, 2013, 48, 93-99.	2.2	21
62	Impaired energyâ€dependent processes underlie acute lead neuropathy. Muscle and Nerve, 2012, 46, 954-956.	2.2	8
63	The effects of large artery ischemia and subsequent recanalization on nerve excitability. Muscle and Nerve, 2011, 44, 841-841.	2.2	7
64	Nerve conduction studies. Australian Family Physician, 2011, 40, 693-7.	0.5	9
65	Corticospinal tract dysfunction and development of amyotrophic lateral sclerosis following electrical injury. Muscle and Nerve, 2010, 42, 288-292.	2.2	13
66	Spontaneous peroneal compartment syndrome causing acute foot drop. Internal Medicine Journal, 2008, 38, 926-930.	0.8	4
67	Post-vaccination encephalomyelitis: Literature review and illustrative case. Journal of Clinical Neuroscience, 2008, 15, 1315-1322.	1.5	198
68	Meningococcal meningitis and a negative cerebrospinal fluid: Case report and its medicolegal implications. EMA - Emergency Medicine Australasia, 2007, 19, 553-555.	1.1	8